Acquist Therapeutics, Inc.

10:00 AM - 10:15 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Acquist develops small molecules that deplete uric acid (UA), an established inflammatory mediator in gout and NASH highly prevalent diseases with grossly unmet needs.
Our drugs block lipogenesis and NASH progression in models with elevated UA (~40% of patients). In liver cells, we sharply reduce UA, triglycerides, lipogenesis and inflammation. Our drugs bifunctionally inhibit regulators of both UA production and excretion (xanthine oxidase and URAT1) at potencies greater than (e.g., allopurinol, febuxostat, lesinurad). Our clinical drug prototype reduced UA below targets in 100% of patients.
Our executives have extensive experience in drug development. Global composition patents are wholly owned. Optimized for 1st-line, once-daily oral dosing, our lead (ACQT1127) is completing animal tox for IND submission and confirmation of activity in these two biomarker-defined populations. The Company is raising a Series A financing and is interested in meeting with qualified investors/partner.
Company Type:
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
1914
Main Therapeutic Focus:
Lead Product in Development:
ACQT1127
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1